{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:56:35Z","timestamp":1793040995698,"version":"4.5.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01423-0","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:15:58Z","timestamp":1746533758000},"page":"1633-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kasireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"1423_CR1","unstructured":"National Psoriasis Foundation. Psoriasis statistics. https:\/\/www.psoriasis.org\/psoriasis-statistics\/. 2022. Accessed 23 July 2024."},{"issue":"4","key":"1423_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1423_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Bohannan B, Mburu S, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12(4):1055\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1423_CR4","unstructured":"American Academy of Dermatology. Psoriasis treatment: biologics. 2022. https:\/\/www.aad.org\/public\/diseases\/psoriasis\/treatment\/medications\/biologics. Accessed 18 Dec 2024."},{"issue":"1","key":"1423_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/jamadermatol.2023.4445","volume":"160","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Noe MH. The best psoriasis medications emerge. JAMA Dermatol. 2024;160(1):99\u2013100.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1423_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1423_CR7","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s12325-022-02065-w","volume":"39","author":"CL Leonardi","year":"2022","unstructured":"Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256\u201369.","journal-title":"Adv Ther"},{"key":"1423_CR8","unstructured":"ILUMYA\u00ae (tildrakizumab-asmn) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2024."},{"key":"1423_CR9","unstructured":"ILUMETRI (tildrakizumab) [prescribing information]. Barcelona, Spain: Almirall, S.A.; 2023."},{"issue":"10091","key":"1423_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE\u00a01 and reSURFACE\u00a02): results from two randomised controlled, phase\u00a03 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"11","key":"1423_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"1423_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1423_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1741-7015-12-93","volume":"12","author":"S Cope","year":"2014","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:93.","journal-title":"BMC Med"},{"issue":"11","key":"1423_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2217\/cer-2018-0065","volume":"7","author":"C Cameron","year":"2018","unstructured":"Cameron C, Hutton B, Druchok C, et al. Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis. J Comp Eff Res. 2018;7(11):1037\u201351.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"1423_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607\u201317.","journal-title":"Med Decis Making"},{"issue":"4","key":"1423_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1018598421607","volume":"7","author":"AP Dempster","year":"1997","unstructured":"Dempster AP. The direct use of likelihood for significance testing. Stat Comput. 1997;7(4):247\u201352.","journal-title":"Stat Comput"},{"issue":"4","key":"1423_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Methodol. 2002;64(4):583\u2013639.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"5","key":"1423_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33(5):618\u201340.","journal-title":"Med Decis Making"},{"issue":"5","key":"1423_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641\u201356.","journal-title":"Med Decis Making"},{"key":"1423_CR20","unstructured":"ClinicalTrials.gov identifier: NCT00585650. Updated May 18, 2023. https:\/\/clinicaltrials.gov\/study\/NCT00585650. Accessed 25 April 2025."},{"key":"1423_CR21","unstructured":"ClinicalTrials.gov identifier: NCT03897088. Updated May 31, 2023. https:\/\/clinicaltrials.gov\/study\/NCT03897088. Accessed 24 April 2025."},{"key":"1423_CR22","unstructured":"Network of Care. Efficacy study of CDP870 in subjects with chronic plaque psoriasis who are candidate for systemic therapy and\/or phototherapy\/photochemotherapy. https:\/\/aging.networkofcare.org\/riverside\/CommunityResources\/ClinicalTrials\/Detail\/NCT00245765. Accessed 25 April 2025."},{"issue":"2","key":"1423_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/14712598.2021.1843629","volume":"21","author":"N AlMutairi","year":"2021","unstructured":"AlMutairi N, Eassa BI. A randomized controlled ixekizumab vs secukinumab trial to study the impact on sexual activity in adult patients with genital psoriasis. Expert Opin Bio Ther. 2021;21(2):297\u20138.","journal-title":"Expert Opin Bio Ther"},{"issue":"6","key":"1423_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40257-016-0229-x","volume":"17","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Villanueva Quintero DG, Echeverria CM, Gu Y, Karunaratne M, Reyes SO. Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab. Am J Clin Dermatol. 2016;17(6):691\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1423_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","volume":"152","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase\u00a03 clinical trials. JAMA Dermatol. 2016;152(6):661\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1423_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","volume":"37","author":"A Asahina","year":"2010","unstructured":"Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase\u00a0II\/III randomized controlled study. J Dermatol. 2010;37(4):299\u2013310.","journal-title":"J Dermatol"},{"issue":"6","key":"1423_CR27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2\u00a0weeks demonstrated superior efficacy compared with dosing every 4\u00a0weeks in patients with psoriasis weighing 90\u00a0kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942\u201354.","journal-title":"Br J Dermatol"},{"issue":"4 Suppl 1","key":"1423_CR28","first-page":"S23","volume":"15","author":"M Augustin","year":"2022","unstructured":"Augustin M, Gottlieb AB, Laws P, et al. Bimekizumab versus secukinumab in plaque psoriasis: higher efficacy translates into benefits in patient-perceived symptoms and health-related quality of life in the BE RADIANT multicenter, randomized, doubleblinded phase\u00a03b trial. J Clin Aesthet Dermatol. 2022;15(4 Suppl 1):S23\u20134.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"9993","key":"1423_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase\u00a03 randomised non-inferiority trial. Lancet. 2015;386(9993):552\u201361.","journal-title":"Lancet"},{"issue":"1","key":"1423_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","volume":"7","author":"J Bagel","year":"2012","unstructured":"Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;7(1):86\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1423_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdv.16558","volume":"35","author":"J Bagel","year":"2021","unstructured":"Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase\u00a03b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021;35(1):135\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1423_CR32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"J Bagel","year":"2017","unstructured":"Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase\u00a03b study. J Am Acad Dermatol. 2017;77(4):667\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1423_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1468-3083.2011.03984.x","volume":"25","author":"R Bissonnette","year":"2011","unstructured":"Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1423_CR34","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","volume":"137","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Harel F, Krueger JG, et al. TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol. 2017;137(8):1638\u201345.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1423_CR35","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.15706","volume":"177","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3\u00a0years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033\u201342.","journal-title":"Br J Dermatol"},{"issue":"3 Supplement","key":"1423_CR36","doi-asserted-by":"publisher","first-page":"AB146","DOI":"10.1016\/j.jaad.2021.06.597","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Thaci D, Papp KA, et al. Bimekizumab vs adalimumab in plaque psoriasis: higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase\u00a03 trial. J Am Acad Dermatol. 2021;85(3 Supplement):AB146.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1423_CR37","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1080\/09546634.2021.1914812","volume":"33","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gordon KB, Lee P, et al. Efficacy, safety, usability, and acceptability of risankizumab 150\u00a0mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022;33(4):2085\u201393.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1423_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1\u00a0year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1423_CR39","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1080\/09546634.2021.1959504","volume":"33","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Armstrong AW, Langley RG, et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatolog Treat. 2022;33(4):2317\u201324.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1423_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1423_CR41","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase\u00a03 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1423_CR42","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1423_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/09546634.2019.1587146","volume":"31","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Lomaga M, Burge R, et al. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52\u00a0weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase\u00a03b clinical trial. J Dermatolog Treat. 2020;31(2):141\u20136.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1423_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase\u00a0III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"1423_CR45","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52\u00a0weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020;133(22):2665\u201373.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1423_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","volume":"31","author":"L Cai","year":"2017","unstructured":"Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase\u00a03, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9271","key":"1423_CR47","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842\u20137.","journal-title":"Lancet"},{"issue":"12","key":"1423_CR48","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1468-3083.2009.03321.x","volume":"23","author":"E Dauden","year":"2009","unstructured":"Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54\u00a0weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23(12):1374\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1423_CR49","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/bjd.14867","volume":"176","author":"AC de Vries","year":"2017","unstructured":"de Vries AC, Thio HB, de Kort WJ, et al. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the psoriasis infliximab vs. etanercept comparison evaluation (PIECE) study. Br J Dermatol. 2017;176(3):624\u201333.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1423_CR50","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09546634.2020.1749546","volume":"33","author":"B Elewski","year":"2022","unstructured":"Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase\u00a03 trials. J Dermatolog Treat. 2022;33(1):261\u20135.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1423_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","volume":"78","author":"BE Elewski","year":"2018","unstructured":"Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26\u00a0weeks of a phase\u00a03, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(1):90-9.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1423_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","volume":"31","author":"LK Ferris","year":"2020","unstructured":"Ferris LK, Ott E, Jiang J, et al. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (one-press), for moderate-to-severe psoriasis: results from the phase\u00a03 ORION study. J Dermatolog Treat. 2020;31(2):152\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"10273","key":"1423_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase\u00a03 trial. Lancet. 2021;397(10273):475\u201386.","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"1423_CR54","first-page":"S23","volume":"14","author":"K Gordon","year":"2021","unstructured":"Gordon K, Foley P, Rich P, et al. Bimekizumab versus ustekinumab in plaque psoriasis: lasting efficacy translates to rapid and sustained improvements in quality of life in the BE VIVID multicenter, randomized, double-blinded phase\u00a0III trial. J Clin Aesthet Dermatol. 2021;14(5 Suppl 1):S23\u20134.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"1423_CR55","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bjd.12636","volume":"170","author":"KB Gordon","year":"2014","unstructured":"Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014;170(3):705\u201315.","journal-title":"Br J Dermatol"},{"issue":"10148","key":"1423_CR56","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase\u00a03 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"4","key":"1423_CR57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase\u00a03 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"12","key":"1423_CR58","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","volume":"139","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal Is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Invest Dermatol. 2019;139(12):2437-46.e1.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1423_CR59","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, et al. A phase\u00a02 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1423_CR60","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598\u2013606.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1423_CR61","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","volume":"76","author":"A Gottlieb","year":"2017","unstructured":"Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1423_CR62","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","volume":"79","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Blauvelt A, Tha\u00e7i D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48\u00a0weeks from 2 phase\u00a03, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302-314.e6.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1423_CR63","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627\u201332 (discussion 32).","journal-title":"Arch Dermatol"},{"issue":"5","key":"1423_CR64","doi-asserted-by":"publisher","first-page":"AB270","DOI":"10.1016\/j.jaad.2016.02.1043","volume":"74","author":"CEM Griffiths","year":"2016","unstructured":"Griffiths CEM, Blauvelt A, Leonardi C, et al. Secukinumab exhibits a favorable safety profile during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;74(5):AB270.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1423_CR65","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"1423_CR66","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","volume":"39","author":"A Igarashi","year":"2012","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase\u00a02\/3 clinical trial. J Dermatol. 2012;39(3):242\u201352.","journal-title":"J Dermatol"},{"issue":"5","key":"1423_CR67","first-page":"33","volume":"11","author":"S Khattri","year":"2018","unstructured":"Khattri S, Goldblum O, Solotkin K, et al. Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis. J Clin Aesthet Dermatol. 2018;11(5):33\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"12","key":"1423_CR68","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/jdv.12046","volume":"27","author":"AB Kimball","year":"2013","unstructured":"Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5\u00a0years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535\u201345.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1423_CR69","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580\u201392.","journal-title":"N Engl J Med"},{"issue":"6 Supplement","key":"1423_CR70","doi-asserted-by":"publisher","first-page":"AB38","DOI":"10.1016\/j.jaad.2020.06.239","volume":"83","author":"JG Krueger","year":"2020","unstructured":"Krueger JG, Pariser D, Muscianisi E, et al. Response to treatment with secukinumab in obese patients with moderate to severe psoriasis. J Am Acad Dermatol. 2020;83(6 Supplement):AB38.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1423_CR71","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA, Schlitt T, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"key":"1423_CR72","doi-asserted-by":"crossref","unstructured":"Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52\u00a0weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase\u00a0III trial (IXORA-P). Br J Dermatol. 2018;178(6):1315\u201323.","DOI":"10.1111\/bjd.16426"},{"issue":"5","key":"1423_CR73","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/bjd.13469","volume":"172","author":"RG Langley","year":"2015","unstructured":"Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5\u00a0years of follow-up. Br J Dermatol. 2015;172(5):1371\u201383.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1423_CR74","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","volume":"79","author":"M Lebwohl","year":"2018","unstructured":"Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48\u00a0weeks of a phase\u00a03, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266-76.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1423_CR75","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","volume":"147","author":"C Leonardi","year":"2011","unstructured":"Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429\u201336.","journal-title":"Arch Dermatol"},{"issue":"21","key":"1423_CR76","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"CL Leonardi","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014\u201322.","journal-title":"N Engl J Med"},{"key":"1423_CR77","doi-asserted-by":"crossref","unstructured":"Mehta NN, Shin DB, Joshi AA, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging. 2018;11(6):e007394.","DOI":"10.1161\/CIRCIMAGING.117.007394"},{"issue":"1","key":"1423_CR78","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase\u00a0II randomized controlled study. J Dermatol Sci. 2016;81(1):44\u201352.","journal-title":"J Dermatol Sci"},{"key":"1423_CR79","unstructured":"Network of Care. An efficacy and safety study of ustekinumab (CNTO 1275) in participants with plaque psoriasis. https:\/\/aging.networkofcare.org\/riverside\/CommunityResources\/ClinicalTrials\/Detail\/NCT00723528. Accessed 25 April 2025."},{"key":"1423_CR80","doi-asserted-by":"crossref","unstructured":"Odnopozova L, Edin A, Sukharev A, et al. Risankizumab for the treatment of moderate to severe plaque psoriasis in the Russian federation. Dermatol Ther (Heidelb). 2022;12(9):2063\u201375.","DOI":"10.1007\/s13555-022-00776-0"},{"issue":"9","key":"1423_CR81","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase\u00a03, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053\u201362.","journal-title":"J Dermatol"},{"issue":"8","key":"1423_CR82","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase\u00a02\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"issue":"5","key":"1423_CR83","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/bjd.12060","volume":"168","author":"JP Ortonne","year":"2013","unstructured":"Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080\u20137.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1423_CR84","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase\u00a0IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1423_CR85","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase\u00a0II dose-ranging study. Br J Dermatol. 2013;168(2):412\u201321.","journal-title":"Br J Dermatol"},{"issue":"10284","key":"1423_CR86","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp KA, Weinberg MA, Morris A, Reich K. IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase\u00a02b study. Lancet. 2021;397(10284):1564\u201375.","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"1423_CR87","first-page":"S26","volume":"14","author":"K Papp","year":"2021","unstructured":"Papp K, Warren RB, Green LJ, et al. Efficacy and safety of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe psoriasis: 52-week results from OASIS-2, a multicenter, randomized, double-blind study. J Clin Aesthet Dermatol. 2021;14(5 Suppl 1):S26.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"Suppl 3","key":"1423_CR88","first-page":"S14","volume":"135","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, You R, Fox T. Secukinumab administration by autoinjector maintains efficacy in moderate to severe plaque psoriasis over 52 weeks: results of the JUNCTURE trial. J Invest Dermatol. 2015;135(Suppl 3):S14.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1423_CR89","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/jdv.12359","volume":"28","author":"C Paul","year":"2013","unstructured":"Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase\u00a02 trial. J Eur Acad Dermatol Venereol. 2013;28(12):1670\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1423_CR90","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","volume":"154","author":"K Reich","year":"2006","unstructured":"Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1423_CR91","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.17351","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954\u201366.","journal-title":"Br J Dermatol"},{"key":"1423_CR92","doi-asserted-by":"crossref","unstructured":"Reich K, Gooderham M, Tha, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394(10198):576\u201386.","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"1423_CR93","doi-asserted-by":"crossref","unstructured":"Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase\u00a0IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507\u201317.","DOI":"10.1111\/jdv.14015"},{"issue":"3","key":"1423_CR94","doi-asserted-by":"publisher","first-page":"AB55","DOI":"10.1016\/j.jaad.2021.06.246","volume":"85","author":"W Rui","year":"2021","unstructured":"Rui W, Li X, Zheng J, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase\u00a03 study. J Am Acad Dermatol. 2021;85(3):AB55.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1423_CR95","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase\u00a0IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1423_CR96","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/1346-8138.15733","volume":"48","author":"SJ Seo","year":"2021","unstructured":"Seo SJ, Shin BS, Lee JH, Jeong H. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: a randomized, phase\u00a0III, double-blind, placebo-controlled study. J Dermatol. 2021;48(6):807\u201317.","journal-title":"J Dermatol"},{"key":"1423_CR97","doi-asserted-by":"crossref","unstructured":"Sigurgeirsson B, Schakel K, Hong CH, et al. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300\u00a0mg in patients with moderate to severe plaque psoriasis: results from the phase\u00a03 randomized, double-blind, placebo-controlled ALLURE study. J Dermatolog Treat. 2022;33(3):1718\u201326.","DOI":"10.1080\/09546634.2021.1902925"},{"issue":"Suppl 9","key":"1423_CR98","first-page":"448","volume":"73","author":"B Sigurgeirsson","year":"2021","unstructured":"Sigurgeirsson B, Browning J, Tyring S, et al. High efficacy, safety, and tolerability of secukinumab injection with 2 ml auto-injector (300\u00a0mg) in adult patients with moderate to severe plaque psoriasis: 52-week results from mature, a randomised, placebo-controlled trial. Arthritis Rheumatol. 2021;73(Suppl 9):448\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1423_CR99","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","volume":"165","author":"BE Strober","year":"2011","unstructured":"Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase\u00a0III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1423_CR100","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/09546634.2012.658015","volume":"24","author":"R Strohal","year":"2013","unstructured":"Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24(3):169\u201378.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1423_CR101","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","volume":"59","author":"H Torii","year":"2010","unstructured":"Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40\u20139.","journal-title":"J Dermatol Sci"},{"issue":"8","key":"1423_CR102","first-page":"943","volume":"11","author":"TF Tsai","year":"2012","unstructured":"Tsai TF, Song M, Shen YK, et al. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial. J Drugs Dermatol. 2012;11(8):943\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1423_CR103","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.143.6.719","volume":"143","author":"S Tyring","year":"2007","unstructured":"Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50\u00a0mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719\u201326.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1423_CR104","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13555-021-00494-z","volume":"11","author":"Y Umezawa","year":"2021","unstructured":"Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase\u00a02\/3 Japanese study. Dermatol Ther (Heidelb). 2021;11(2):513\u201328.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1423_CR105","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52\u00a0weeks. J Invest Dermatol. 2019;139(5):1054\u201362.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1423_CR106","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1423_CR107","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjd.18623","volume":"183","author":"RB Warren","year":"2020","unstructured":"Warren RB, Barker J, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-alpha inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2020;183(1):60\u201370.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1423_CR108","first-page":"1845","volume":"25","author":"HZ Yang","year":"2012","unstructured":"Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl). 2012;25(11):1845\u201351.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"1423_CR109","first-page":"166","volume":"12","author":"X Zhu","year":"2013","unstructured":"Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase\u00a03 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166\u201374.","journal-title":"J Drugs Dermatol"},{"key":"1423_CR110","unstructured":"ClinicalTrials.gov identifier: NCT00629772. Updated September 9, 2011. https:\/\/www.clinicaltrials.gov\/study\/NCT00629772. Accessed 25 April 2025."},{"key":"1423_CR111","unstructured":"ClinicalTrials.gov identifier: NCT02134210. Updated June 28, 2019. https:\/\/clinicaltrials.gov\/study\/NCT02134210. Accessed 25 April 2025."},{"issue":"3","key":"1423_CR112","volume":"30","author":"K Agelopoulos","year":"2021","unstructured":"Agelopoulos K, Hambuchen C, Becker R, et al. Cutaneous nerve fiber architecture is altered in lesional psoriatic skin and recovers upon treatment with secukinumab. Exp Dermatol. 2021;30(3):e89.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1423_CR113","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour JP, Fowler JF, et al. Phase\u00a0III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623\u201331.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1423_CR114","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bjd.15722","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Ferris LK, Yamauchi PS, et al. Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase\u00a0IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). Br J Dermatol. 2017;177(6):1552\u201361.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1423_CR115","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12325-021-01899-0","volume":"39","author":"L Cai","year":"2022","unstructured":"Cai L, Li L, Cheng H, et al. Efficacy and safety of HLX03, an adalimumab biosimilar, in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, phase\u00a0III study. Adv Ther. 2022;39(1):583\u201397.","journal-title":"Adv Ther"},{"issue":"5","key":"1423_CR116","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","volume":"152","author":"SR Feldman","year":"2005","unstructured":"Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152(5):954\u201360.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1423_CR117","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","volume":"159","author":"SR Feldman","year":"2008","unstructured":"Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704\u201310.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1423_CR118","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40259-021-00502-w","volume":"35","author":"SR Feldman","year":"2021","unstructured":"Feldman SR, Reznichenko N, Pulka G, et al. Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase\u00a0III study. BioDrugs. 2021;35(6):735\u201348.","journal-title":"BioDrugs"},{"issue":"Suppl 9","key":"1423_CR119","first-page":"3620","volume":"74","author":"B Finck","year":"2022","unstructured":"Finck B, Tang H, Jensen K, Civoli F, Tatarewicz S. Efficacy and safety similarity of biosimilar adalimumab-aqvh to adalimumab in patients with moderate-to-severe chronic plaque psoriasis: a phase\u00a0III study. Arthritis Rheumatol. 2022;74(Suppl 9):3620\u20131.","journal-title":"Arthritis Rheumatol"},{"key":"1423_CR120","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, D Tha\u00e7i, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928\u201338.","DOI":"10.1111\/bjd.15152"},{"key":"1423_CR121","doi-asserted-by":"crossref","unstructured":"Hercogova J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase\u00a0III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB110222 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316\u201326.","DOI":"10.1111\/bjd.18220"},{"issue":"6","key":"1423_CR122","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","volume":"153","author":"GG Krueger","year":"2005","unstructured":"Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase\u00a0III trial. Br J Dermatol. 2005;153(6):1192\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1423_CR123","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase\u00a0III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"1423_CR124","first-page":"13","volume":"63","author":"C Leonardi","year":"2022","unstructured":"Leonardi C, Sator P, Morita A, et al. Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial. Australas J Dermatol. 2022;63(Suppl 1):13\u20134.","journal-title":"Australas J Dermatol"},{"key":"1423_CR125","doi-asserted-by":"crossref","unstructured":"Menter A, Arenberger P, Balser S, et al. Similar efficacy, safety and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized phase\u00a0III VOLTAIRE-PSO study. Expert Opin Biol Ther. 2021;21(1):87\u201396.","DOI":"10.1080\/14712598.2021.1851362"},{"issue":"6","key":"1423_CR126","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","volume":"76","author":"K Papp","year":"2017","unstructured":"Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase\u00a0III study. J Am Acad Dermatol. 2017;76(6):1093\u2013102.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1423_CR127","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjd.19262","volume":"184","author":"K Reich","year":"2021","unstructured":"Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425\u201336.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1423_CR128","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/09546634.2019.1628172","volume":"31","author":"K Reich","year":"2020","unstructured":"Reich K, Foley P, Han C, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. J Dermatolog Treat. 2020;31(6):617\u201323.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1423_CR129","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000237871","volume":"219","author":"K Reich","year":"2009","unstructured":"Reich K, Segaert S, Van De Kerkhof P, et al. Once-weekly administration of etanercept 50\u00a0mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology. 2009;219(3):239\u201349.","journal-title":"Dermatology"},{"issue":"3","key":"1423_CR130","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","volume":"158","author":"D Revicki","year":"2008","unstructured":"Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158(3):549\u201357.","journal-title":"Br J Dermatol"},{"key":"1423_CR131","doi-asserted-by":"crossref","unstructured":"Samtsov AV, Bakulev AL, Khairutdinov VR, et al. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: a randomized controlled trial. PLoS ONE. 2022;17(2):e0263214.","DOI":"10.1371\/journal.pone.0263214"},{"issue":"9504","key":"1423_CR132","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase\u00a0III trial. Lancet. 2006;367(9504):29\u201335.","journal-title":"Lancet"},{"key":"1423_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109248","volume":"112","author":"C Yu","year":"2022","unstructured":"Yu C, Zhang F, Ding Y, et al. A randomized, double-blind phase\u00a0III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis. Int Immunopharmacol. 2022;112: 109248.","journal-title":"Int Immunopharmacol"},{"key":"1423_CR134","unstructured":"ClinicalTrials.gov identifier: NCT01358578. Updated January 5, 2021. https:\/\/clinicaltrials.gov\/study\/NCT01358578. Accessed 25 April 2025."},{"key":"1423_CR135","unstructured":"ClinicalTrials.gov identifier: NCT00735787. Updated November 1, 2010. https:\/\/clinicaltrials.gov\/study\/NCT00735787. Accessed 25 April 2025."},{"key":"1423_CR136","unstructured":"ClinicalTrials.gov identifier: NCT01646177. Updated July 28, 2020. https:\/\/clinicaltrials.gov\/study\/NCT01646177. Accessed 25 April 2025."},{"key":"1423_CR137","unstructured":"Network of Care. Vascular inflammation in psoriasis trial (The VIP Trial). https:\/\/mentalhealth.networkofcare.org\/Lake\/CommunityResources\/ClinicalTrials\/Detail\/NCT01553058. Accessed 25 April 2025."},{"issue":"2","key":"1423_CR138","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5114\/ada.2019.91496","volume":"38","author":"N AlMutairi","year":"2021","unstructured":"AlMutairi N, Eassa BI. Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature. Postepy Dermatol Alergol. 2021;38(2):281\u20138.","journal-title":"Postepy Dermatol Alergol"},{"issue":"3 Supplement","key":"1423_CR139","doi-asserted-by":"publisher","first-page":"AB25","DOI":"10.1016\/j.jaad.2022.06.133","volume":"87","author":"M Augustin","year":"2022","unstructured":"Augustin M, Gooderham M, Gottlieb AB. Bimekizumab versus secukinumab in plaque psoriasis: reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase\u00a03b trial. J Am Acad Dermatol. 2022;87(3 Supplement):AB25.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1423_CR140","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","volume":"8","author":"J Bagel","year":"2018","unstructured":"Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb). 2018;8(4):571\u20139.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1423_CR141","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/jdv.14391","volume":"31","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Mehlis S, et al. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. J Eur Acad Dermatol Venereol. 2017;31(10):1693\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1423_CR142","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1423_CR143","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Alavi A, et al. A phase\u00a0IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Invest Dermatol. 2020;140(1):85-93.e2.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1423_CR144","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784-93.e2.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1423_CR145","first-page":"1226","volume":"15","author":"AB Gottlieb","year":"2016","unstructured":"Gottlieb AB, Blauvelt A, Prinz JC, et al. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52\u00a0weeks: results of the FEATURE trial. J Drugs Dermatol. 2016;15(10):1226\u201334.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1423_CR146","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bjd.18331","volume":"182","author":"AB Gottlieb","year":"2020","unstructured":"Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889\u201399.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1423_CR147","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"9993","key":"1423_CR148","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase\u00a03 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"1423_CR149","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","volume":"166","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3\u00a0years. Br J Dermatol. 2012;166(4):861\u201372.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1423_CR150","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/jdv.14073","volume":"31","author":"JP Lacour","year":"2017","unstructured":"Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52\u00a0weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1423_CR151","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2013results of two phase\u00a03 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"2","key":"1423_CR152","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11136-019-02296-5","volume":"29","author":"RGB Langley","year":"2020","unstructured":"Langley RGB, Reich K, Strand V, et al. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase\u00a0III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020;29(2):369\u201380.","journal-title":"Qual Life Res"},{"issue":"14","key":"1423_CR153","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase\u00a03 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"1423_CR154","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2133.2009.09491.x","volume":"162","author":"M Lebwohl","year":"2010","unstructured":"Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162(1):137\u201346.","journal-title":"Br J Dermatol"},{"issue":"9625","key":"1423_CR155","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665\u201374.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"1423_CR156","first-page":"S16","volume":"135","author":"C Leonardi","year":"2015","unstructured":"Leonardi C, Blauvelt A, Langley R, et al. Maintenance of efficacy results from UNCOVER-1: a phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis. J Invest Dermatol. 2015;135(Suppl 3):S16.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1423_CR157","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/09546634.2020.1750552","volume":"33","author":"N Li","year":"2022","unstructured":"Li N, Teeple A, Muser E, You Y, Song M, Armstrong AW. Work\/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study. J Dermatol Treat. 2022;33(1):278\u201383.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1423_CR158","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1\u00a0year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):e1-31.","journal-title":"J Am Acad Dermatol"},{"key":"1423_CR159","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/rheumatology\/keaa111.272","volume":"59","author":"JF Merola","year":"2020","unstructured":"Merola JF, Li S, Hsu MC, et al. Guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported PSA in the randomised, double-blind, head-to-head comparison study eclipse over 1\u00a0year. Rheumatology. 2020;59:2020\u2013104.","journal-title":"Rheumatology"},{"issue":"1","key":"1423_CR160","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1423_CR161","doi-asserted-by":"crossref","unstructured":"Noe MH, Wan MT, Shin DB, et al. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the vascular inflammation in psoriasis trial: a randomized controlled study. J Am Acad Dermatol. 2019;81(4):923\u201330.","DOI":"10.1016\/j.jaad.2019.05.080"},{"issue":"6","key":"1423_CR162","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1586\/17469872.3.6.657","volume":"3","author":"JP Ortonne","year":"2008","unstructured":"Ortonne JP, Griffiths CEM, Dauden E, et al. Efficacy and safety of continuous versus paused etanercept teatment in patients with moderate-to-severe psoriasis over 54\u00a0weeks: the CRYSTEL study. Expert Rev Dermatol. 2008;3(6):657\u201365.","journal-title":"Expert Rev Dermatol"},{"issue":"2","key":"1423_CR163","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et al. A prospective phase\u00a0III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"13","key":"1423_CR164","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1423_CR165","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/2475530319867095","volume":"4","author":"K Papp","year":"2019","unstructured":"Papp K, Blauvelt A, Sullivan J, et al. Ixekizumab-an effective and safe treatment for moderate-to-severe plaque psoriasis in patients previously treated with other IL-17 inhibitors: results from IXORA-P. J Psoriasis Psoriatic Arthritis. 2019;4(4):180\u20135.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"9625","key":"1423_CR166","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384.","journal-title":"Lancet"},{"issue":"9","key":"1423_CR167","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jdv.14910","volume":"32","author":"KA Papp","year":"2018","unstructured":"Papp KA, Blauvelt A, Kimball AB, et al. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol. 2018;32(9):1515\u201322.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1423_CR168","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","volume":"152","author":"KA Papp","year":"2005","unstructured":"Papp KA, Tyring S, Lahfa M, et al. A global phase\u00a0III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304\u201312.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1423_CR169","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52\u00a0weeks of treatment: results from IXORA-S, a phase\u00a03 study. J Am Acad Dermatol. 2019;80(1):70-9.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1423_CR170","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 3","key":"1423_CR171","first-page":"S14","volume":"135","author":"JC Prinz","year":"2015","unstructured":"Prinz JC, Blauvelt A, Gottlieb A, You R, Fox T. Secukinumab administration by pre-filled syringe maintains efficacy in moderate to severe plaque psoriasis over 52 weeks: results of the FEATURE trial. J Invest Dermatol. 2015;135(Suppl 3):S14.","journal-title":"J Invest Dermatol"},{"issue":"19","key":"1423_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3700","volume":"100","author":"L Puig","year":"2020","unstructured":"Puig L, Lomaga M, Hollister K, Dutronc Y, Berggren L, Van De Kerkhof P. An analysis of patient-reported outcomes in IXORA-S: comparing ixekizumab and ustekinumab over 52\u00a0weeks in moderate-to-severe psoriasis. Acta Derm Venereol. 2020;100(19):1\u20137p.","journal-title":"Acta Derm Venereol"},{"issue":"10273","key":"1423_CR173","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"10201","key":"1423_CR174","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase\u00a03, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"6","key":"1423_CR175","doi-asserted-by":"publisher","first-page":"AB31","DOI":"10.1016\/j.jaad.2020.06.212","volume":"83","author":"K Reich","year":"2020","unstructured":"Reich K, Gottlieb AB, Guenther L, et al. Clinical responses by self-reported PsA status at baseline among patients with moderate to severe psoriasis treated with guselkumab versus secukinumab: week\u00a048 results from the ECLIPSE study. J Am Acad Dermatol. 2020;83(6):AB31.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1423_CR176","first-page":"381","volume":"17","author":"K Reich","year":"2007","unstructured":"Reich K, Nestle FO, Wu Y, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17(5):381\u20136.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1423_CR177","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","volume":"167","author":"K Reich","year":"2012","unstructured":"Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab certolizumab pegol: results of a phase\u00a0II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180\u201390.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1423_CR178","doi-asserted-by":"publisher","first-page":"AB257","DOI":"10.1016\/j.jaad.2018.05.1019","volume":"79","author":"K Reich","year":"2018","unstructured":"Reich K, Gottlieb A, Lebwohl M, Kisa R, Frueh J. Secukinumab shows sustained efficacy in difficult-to-treat palmoplantar, nail, and scalp psoriasis: long-term results from three phase\u00a0III placebo-controlled randomized trials. J Am Acad Dermatol. 2018;79(3):AB257.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1423_CR179","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.12070","volume":"168","author":"P Rich","year":"2013","unstructured":"Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase\u00a0II regimen-finding study. Br J Dermatol. 2013;168(2):402\u201311.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1423_CR180","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjd.12632","volume":"170","author":"P Rich","year":"2014","unstructured":"Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398\u2013407.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1423_CR181","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"JH Saurat","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558\u201366.","journal-title":"Br J Dermatol"},{"issue":"597","key":"1423_CR182","first-page":"2016","volume":"75","author":"D Thaci","year":"2016","unstructured":"Thaci D, Papp K, Reich K, et al. Treatment with tildrakizumab, an anti-IL-23p19 monoclonal antibody, improves health-related quality of life in patients with chronic plaque psoriasis. Ann Rheum Dis. 2016;75(597):2016\u2013106.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1423_CR183","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase\u00a0III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154\u201363.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"1423_CR184","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","volume":"11","author":"Y Umezawa","year":"2021","unstructured":"Umezawa Y, Asahina A, Imafuku S, et al. Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results. Dermatol Ther (Heidelb). 2021;11(3):943\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1423_CR185","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/jdv.13702","volume":"30","author":"F Valenzuela","year":"2016","unstructured":"Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase\u00a03 study. J Eur Acad Dermatol Venereol. 2016;30(10):1753\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1423_CR186","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jdv.14033","volume":"31","author":"P Van De Kerkhof","year":"2017","unstructured":"Van De Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1423_CR187","first-page":"1177","volume":"159","author":"PCM Van De Kerkhof","year":"2008","unstructured":"Van De Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50\u00a0mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159(5):1177\u201385.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1423_CR188","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"4","key":"1423_CR189","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","volume":"10","author":"N Wasel","year":"2020","unstructured":"Wasel N, Thaci D, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase\u00a03, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663\u201370.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1423_CR190","unstructured":"ClinicalTrials.gov identifier: NCT01241591. Updated December 26, 2018. https:\/\/clinicaltrials.gov\/study\/NCT01241591. Accessed 25 April 2025."},{"issue":"2","key":"1423_CR191","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40259-021-00470-1","volume":"35","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi CL, Gaylis N, et al. Treatment with SDZ-ADL, an adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase\u00a0III studies (ADMYRA and ADACCESS). BioDrugs. 2021;35(2):229\u201338.","journal-title":"BioDrugs"},{"issue":"1","key":"1423_CR192","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase\u00a0III trial. J Am Acad Dermatol. 2008;58(1):106\u201315.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1423_CR193","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1346-8138.2012.01521.x","volume":"39","author":"H Nakagawa","year":"2012","unstructured":"Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase\u00a02\/3 trial. J Dermatol. 2012;39(9):761\u20139.","journal-title":"J Dermatol"},{"key":"1423_CR194","unstructured":"ClinicalTrials.gov identifier: NCT02016105. Updated May 30, 2017. https:\/\/clinicaltrials.gov\/study\/NCT02016105. Accessed 25 April 2025."},{"issue":"9494","key":"1423_CR195","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase\u00a0III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367\u201374.","journal-title":"Lancet"},{"issue":"6","key":"1423_CR196","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/09546630701646172","volume":"18","author":"DA Revicki","year":"2007","unstructured":"Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase\u00a0III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341\u201350.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1423_CR197","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/09546630601121060","volume":"18","author":"R Shikiar","year":"2007","unstructured":"Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase\u00a0II randomized controlled trial. J Dermatolog Treat. 2007;18(1):25\u201331.","journal-title":"J Dermatolog Treat"},{"key":"1423_CR198","unstructured":"ClinicalTrials.gov identifier: NCT01597245. Updated June 26, 2020. https:\/\/clinicaltrials.gov\/study\/NCT01597245. Accessed 25 April 2025."},{"key":"1423_CR199","first-page":"345","volume":"75","author":"AB Gottlieb","year":"2016","unstructured":"Gottlieb AB, Thaci D, Blauvelt A, Bhosekar V, Milutinovic M, Karyekar C. Sustained improvements in skin symptoms, physical functioning, and quality of life with secukinumab versus ustekinumab in patients with moderate-to-severe psoriasis and concomitant psoriatic arthritis: 52\u00a0week results from the clear study. Ann Rheum Dis. 2016;75:345\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1423_CR200","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","volume":"82","author":"L Puig","year":"2020","unstructured":"Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase\u00a03 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1423_CR201","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.18143","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304\u201315.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1423_CR202","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase\u00a0III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1423_CR203","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"1423_CR204","first-page":"CD011535","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1423_CR205","doi-asserted-by":"publisher","first-page":"1964420","DOI":"10.1080\/19420862.2021.1964420","volume":"13","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wang Y, Wan Q, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021;13(1):1964420.","journal-title":"MAbs"},{"issue":"2","key":"1423_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100261","volume":"4","author":"SG Daniele","year":"2024","unstructured":"Daniele SG, Eldirany SA, Damiani G, Ho M, Bunick CG. Structural basis for p19 targeting by anti-IL-23 biologics: correlations with short- and long-term efficacy in psoriasis. JID Innov. 2024;4(2):100261.","journal-title":"JID Innov"},{"key":"1423_CR207","unstructured":"Taltz\u00ae (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2024."},{"key":"1423_CR208","unstructured":"Tremfya\u00ae (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2023."},{"key":"1423_CR209","unstructured":"Skyrizi\u00ae (risankizumab-rzaa) [prescribing information]. North Chicago, IL: AbbVie, Inc.; 2024."},{"issue":"5","key":"1423_CR210","first-page":"CD011535","volume":"5","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1423_CR211","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"}],"updated-by":[{"DOI":"10.1007\/s13555-025-01527-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01423-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01423-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:37:55Z","timestamp":1757169475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01423-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":211,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01423-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-025-01527-7","URL":"https:\/\/doi.org\/10.1007\/s13555-025-01527-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Lebwohl is an Editorial Board member of\n                      Dermatology and Therapy\n                      who was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. He is an employee of Mount Sinai; receives research funds from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen,\u00a0Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio Inc., Apogee, Arcutis, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Andr\u00e9 Carvalho acted as a consultant and\/or speaker for and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceuticals Inc., LEO Pharma, Novartis, Sun Pharma, and UCB. Akihiko Asahina has received honoraria and\/or research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho Co., Ltd., Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sun Pharma, Taiho Pharma, Torii Pharmaceutical Co., Ltd., and UCB. Jianzhong Zhang reports nothing to disclose. Mir Sohail Fazeli, Ellen Kasireddy, and Paul Serafini report employment with Evidinno Outcomes Research Inc. Thomas Ferro and Ranga Gogineni report employment with Sun Pharmaceutical Industries Inc. Diamant Tha\u00e7i is an advisor, speaker, or consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen, Kyowa Kirin, L'Or\u00e9al, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi\/Genzyme, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}